Search PubMed⌕ Search

Biomedical subjects

T Han

Publications and source records attributed to T Han.

At least 181 records · Page 10Linked to original sources
PubMed1980

Indomethacin-mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients.

Indomethacin (prostaglandin synthetase inhibitor) was found to be capable of enhancing the mitogen-induced lymphocyte proliferative responses of healthy subjects and patients with lung cancer. A whole-blood culture technique was used. Indomethacin had no mitogenic activity. We observed a greater enhancement of lymphocyte response by indomethacin in weak responders as compared with strong responders in healthy subjects and lung cancer patients. A greater enhancement was also noted in lung cancer patients with active disease as compared with lung cancer patients in remission. In a separated cell culture system, the indomethacin exerted no effect on purified T cells in the absence of monocytes, while this agent exerted its enhancement effect on T lymphocyte response in the presence of autologous monocytes of lung cancer patients. This suggests that monocytes (suppressor cells) may secrete prostaglandins, which are responsible for the impairment of T lymphocyte response in lung cancer patients.

Adult↗
PubMed1980

Malignant lymphoma of pre-T-cell type terminating in acute myelocytic leukemia. A case report with enzymic and immunologic marker studies.

We report a case of a T-zone malignant lymphoma of a cervical lymph node developing in a 25-year-old man. Only 14% of the marrow was originally involved, but within two months massive, leukemic dissemination ensued. The blast cells were unable to bind sheep erythrocytes (E) but expressed human thymus leukemia antigen (HTLA) and common ALL-stem-cell (cALL) antigen and had high terminal deoxynucleotidyl transferase (TdT) and acid phosphatase activity. These findings suggest a malignant lymphoproliferative disorder of pre-T-cell type. Complete remission was achieved with intensive chemotherapy. Two months later, acute myelomonocytic leukemia was diagnosed; at this time, over 90% of the blast cells were peroxidase, sudan black, and chloracetate-esterase positive. Consistent with loss of high TdT activity and HTLA and cALL antigens, 86% of the blasts now expressed Ia-like antigens. Cytogenetic studies demonstrated hyperdiploidy. Reports of granulocytic leukemia in lymphoma are reviewed in the context of the above findings and the hypothesis that a leukemogenic factor affects a multipotential stem cell.

Acid Phosphatase↗
PubMed1980

Role of suppressor cells in depression of T lymphocyte proliferative response in untreated and treated Hodgkin's disease.

The present study was undertaken to elucidate the type and the role of suppressor cells on T lymphocyte response to PHA in untreated and treated patients with Hodgkin's disease. The mean value of peripheral blood T lymphocyte response to PHA in untreated or treated patients was lower than that in healthy subjects. However, the difference was not statistically significant. There was no significant difference in T lymphocyte response between localized and generalized stage or between different cell types in both active and remission Hodgkin's disease patients. The mean T lymphocyte response to PHA of active patients without systemic symptoms (A), on the other hand, was significantly higher than that of active patients with systemic symptoms (B). The mean value of T lymphocyte response in the presence of monocyte-enriched E- cells was significantly lower, whereas the mean value in the presence of monocyte-depleted E- cells was only moderately lower than that in the absence of these non-T cells in active patients. The mean value of PHA response of T lymphocytes with monocyte-enriched or monocyte-depleted E- cells was only slightly lower than PHA response without these cells in remission patients. No suppressor cell activity of T cells was observed in both active and remission patients. The only significant difference in the suppressor cell activity of monocyte-enriched E- cells on the T lymphocyte response to PHA was observed between localized and generalized stage in patients with active disease. Unlike peripheral blood monocyte-enriched E- cells, the splenic monocyte-enriched E- cells possessed no significant suppressor cell activity on the splenic T lymphocyte response to PHA in active Hodgkin's disease patients. These observations suggest that the depression of in vitro cell-mediated immunity seen in patients with active Hodgkin's disease may be due to the non-specific suppression of T lymphocyte response by monocytes, in addition to a possibly intrinsic defect of T lymphocytes.

Adult↗
PubMed1980

Appraisal of aspiration cytology in management of Hodgkin's disease.

The value of aspiration cytology in the management of Hodgkin's disease is shown in this study of 228 patients and 403 aspirations; 385 from lymph nodes and 18 from extranodal masses. In all patients the initial diagnosis was established on surgical biopsy. Aspirates were helpful in staging, defining extension of unusual radiation fields, and in recognizing residual disease and relapses after therapy. Adequate material was obtained in 80% of aspirations. The diagnosis of Hodgkin's disease could not be established in the adequate cytologic sample in 9.9% of cases. In 5.5%, the diagnosis was that of benign reactive hyperplasia and in 4.4%, non-Hodgkin's lymphoma. Unsatisfactory material was usually obtained from nodes less than 1 cm in diameter or from residual lesions following radiation or chemotherapy. Only 14 of 93 such lesions proved to have active disease during follow up. There were no significant complications. Characteristics of the varied aspects of aspirated tumor cells found in Hodgkin's disease are described.

Adolescent↗
PubMed1980

Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease.

The splenic T and B cell distribution in 79 patients with untreated Hodgkin's disease was quite similar to that in 15 control patients with non-Hodgkin's lymphoma or carcinoma. The mean T lymphocyte percentage was slightly higher in involved spleens than in uninvolved spleens of patients with Hodgkin's disease. There was no significant difference in the T and B cell distribution between tumor area and tumor-free area of the same spleens of Hodgkin's disease patients. Splenic T and B cell distribution did not correlate well with the clinical features of Hodgkin's disease. The splenic T cell percentage was significantly lower than that of the peripheral blood T cell percentage (P less than 0.05), while the splenic B cell percentage was significantly higher than peripheral blood B cell percentage (P less than 0.01) in 13 patients with untreated Hodgkin's disease. The splenic T lymphocyte response to PHA was significantly higher than the peripheral blood T lymphocyte response (P less than 0.05), and the splenic B lymphocyte response to PHA, in the presence of irradiated autologous splenic T lymphocytes, was also significantly higher than the peripheral blood B lymphocyte response (P less than 0.05) in 8 and 6 patients with untreated Hodgkin's disease, respectively. Since the control splenic cells, utilized in this study were obtained not from patients with non-neoplastic disease, but from patients with neoplastic disease other than Hodgkin's disease, our data are not conclusive, but only suggestive of normal T and B cell distribution and function in uninvolved spleens of patients with untreated Hodgkin's disease.

Adolescent↗
PubMed1980

Malignant lymphoma with a high content of epithelioid histiocytes: report of T-cell variant of so-called Lennert lymphoma and review of the literature.

The present report describes the first case of well-differentiated nodular lymphocytic lymphoma evolving into Lennert lymphoma of T-cell origin. A 58-year-old white female developed malignant lymphoma, well-differentiated, lymphocytic type, nodular, with focal bone marrow involvement (stage IV) in May 1975. She received 16 cycles of cyclophosphamide and prednisone combination chemotherapy which was completed in October 1976. A complete remission was achieved. In December 1976, she relapsed and was treated with cyclophosphamide, vincristine, bleomycin, and prednisone until May 1977. Lymphadenopathy decreased until August 1978, but then increased again. Biopsy of an axillary lymph node was interpreted as Lennert lymphoma. She received methotrexate, cyclophosphamide, vincristine, adriamycin, and prednisone beginning in September 1978. When last seen in November 1979, she was in partial remission. Lymphoid cells obtained from lymph node which was involved with Lennert lymphoma consisted of 93% standard E-rosettes and 83% gravity E-rosettes. Cytoplasmic immunoglobulin on frozen sections was negative, but acid phosphatase (ACP) and alpha-naphthyl acetate esterase reactions were strongly positive. These findings support a T-cell proliferation in Lennert lymphoma. A review of the literature reveals only four cases of Lennert lymphoma of T-cell origin.

Drug Therapy, Combination↗
PubMed1980

Expression of MLR-S in human myeloid, monocytic and erythroid cell differentiation.

The present study describes a comparative study of MLR-S of various stages of fresh and cultured normal or leukemic myeloid, monocytic and erythroid cells. "One-way" MLR was performed, using a slightly modified whole blood method. Fresh leukemic myeloblasts from patients with acute myelocytic leukemia or chronic myelocytic leukemia, in blastic crisis possess a strong MLR-S whereas fresh granulocytes from patients with chronic myelocytic leukemia or from healthy subjects possess no MLR-S. Cultured leukemic myeloblasts from KG-1 or ML-1 cell line possess a very strong or a moderate MLR-S, whereas cultured leukemic promyelocytes from HL-60 cell line possess little or no MLR-S. Fresh leukemic erythroblasts or cultured leukemic erythroblasts from K-562 cell line exert a strong MLR-S whereas fresh erythrocytes exert no MLR-S. Cultured monoblasts from HPL-SK-1 or Murray cell line possess a very strong MLR-S whereas fresh monocytes from healthy subjects or from a patient with chronic monocytic leukemia possess a moderate MLR-S. These observations clearly indicate that there is a good correlation between the MLR-S and the cell differentiation stage. Observations in the present study also support the hypothesis that the MLR-S is a differentiation antigen which is completely lost by the terminal stage of myeloid or erythroid cell maturation or partially lost by the terminal stage of monocytic cell maturation.

Cell Line↗
PubMed1979

Establishment and characterization of human B-lymphocytic lymphoma cell lines (BALM-3, -4 and -5); intraclonal variation in the B-cell differentiation stage.

This study describes the establishment of three non-Burkitt B-lymphoma cell lines (BALM-3, BALM-4 and BALM-5) originating from the pleural effusion of a patient with a poorly differentiated diffuse lymphocytic lymphoma. The cells of BALM-3, -4 and -5 exhibited a number of properties which distinguish them from the usual B-cell type lymphoblastoid cell lines. Thus, they lacked the Epstein-Barr virus genome and had abnormal chromosome constitutions including a 14q+ marker. The presence of the identical surface immunoglobulin isotypes (gamma and chi chain determinants), and Ia-like B-cell-associated antigen in the cultured cells and in the "fresh" lymphoma cells in vivo was demonstrated. These findings strongly suggested that these cell lines have B-cell characteristics and were derived from the original tumor cell population. BALM-5 cells, however, showed somewhat different growth, cell surface marker profile and functional characteristics compared to those of BALM-3, and -4 cells. These variations suggest that the BALM-5 cells were probably at different stages of B-cell maturation than those of BALM-3 and -4, even though all three cell lines (established in three separate flasks) originated from the cells of the same pleural effusion of a lymphoma with monoclonal B-cell characteristics.

Antigens, Surface↗
PubMed1979

In vitro functional studies of mononuclear cells in patients with CLL: evidence for functionally normal T lymphocytes and monocytes and abnormal B lymphocytes.

In vitro functional studies of mononuclear cells from 34 patients with B-cell type CLL were investigated and the results of these studies were as follows: 1) The T lymphocytes from patients with CLL were capable of responding normally to PHA or PWM, of inducing allogeneic normal B lymphocytes to respond to these mitogens and of stimulating normally to allogeneic lymphocytes in "one-way" mixed lymphocyte reaction; 2) The monocytes from these patients were capable of enhancing the T lymphocyte response to mitogens and of stimulating normally to allogeneic lymphocytes; and 3) The leukemic B lymphocytes were incapable of responding to mitogens even in the presence of normal T lymphocytes and their enhancer cell activity on T lymphocyte response or their stimulating capacity on allogeneic lymphocytes was depressed. These observations suggest that the T lymphocytes and monocytes from patients with CLL are functionally normal while the leukemic B lymphocytes from these patients are functionally abnormal.

Adult↗
PubMed1979

Cultured human leukemic non-T/non-B lymphoblasts and their stimulating capacity in "one-way" mixed lymphocyte reaction: suggestive evidence for early T-cell or B-cell precursors.

It is now well recognized that a large proportion of cases with acute lymphoblastic leukemia are classified as non-T/non-B neoplastic disease. The origin of leukemic non-T/non-B cells is at present not known. It has been shown that fresh or cultured leukemic T lymphoblasts exert no stimulating capacity while leukemic B lymphoblasts exert a strong stimulation in "one-way" mixed lymphocyte reaction. It has also been shown that fresh leukemic cells from some patients with non-T/non-B acute lymphoblastic leukemia possess a strong stimulation while leukemic cells from other patients with this disease possess no stimulation on allogeneic lymphocytes. The present study shows that cultured leukemic lymphoblasts from 3 non-T/non-B cell lines (NALL-1, NALM-6 and NALM-16) consistently exert a strong stimulation on allogeneic lymphocytes. On the other hand, cultured leukemic lymphoblasts from 2 non-T/non-B cell lines (REH and KM-3) consistently fail to stimulate in "one-way" mixed lymphocyte reaction. Our data clearly support the speculation that leukemic non-T/non-B cells which possess the stimulating capacity may represent less differentiated leukemic B lymphoid cells (pre-B cells) and leukemic non-T/non-B cells which possess no stimulating capacity may represent less differentiated leukemic T lymphoid cells (per-T cells).

Animals↗
PubMed1979

T-cell chronic lymphocytic leukemia: report of a case and review of the literature.

We recently observed a unique case of T-cell type chronic lymphocytic leukemia, documented by cell surface marker analyses. Immunologic tests at the time of diagnosis were as follows: 1) skin tests were negative; 2) in vitro lymphocyte responses to antigens or pokeweed mitogen were absent; 3) in vitro lymphocyte responses to phytohemagglutinin, concanavalin-A or allogeneic cells were low but significant; and 4) stimulating capacity of leukemic T cells were absent. Chromosomal analysis of bone marrow showed a pattern of 45 chromosomes with a marker chromosome. Terminal deoxynucleotidyl transferase activity was very low. Patient responded extremely well to COP (cyclophosphamide-oncovin-prednisone) therapy. Patient died of recurrent transitional cell carcinoma while his leukemia was in complete remission, approximately 20 months after the diagnosis of T-cell CLL.

Aged↗
PubMed1979

Bronchogenic carcinoma in chronic lymphocytic leukemia.

Fourteen cases of bronchogenic carcinoma were found in 191 patients with chronic lymphocytic leukemia seen at the Rosewell Park Memorial Institute, Buffalo, NY, from 1951 to 1976. Four of these were not diagnosed until the time of autopsy. There was an average lag of nine months between the onset of symptoms and signs suggestive of bronchogenic carcinoma and its diagnosis. In patients with chronic lymphocytic leukemia, a high index of suspicion for bronchogenic carcinoma is necessary fo its early detection.

Adult↗
PubMed1979

Human myeloma cells and their strong stimulating capacity in 'one-way' mixed lymphocyte reaction: a comparative study with leukaemic B lymphoid cells.

Cultured human myeloma cells (ARH-77, RPMI-8226 and U-266), like leukaemic B lymphoid cells, consistently exerted a strong stimulating capacity on allogeneic lymphocytes in the 'one-way' mixed lymphocyte reaction. An optimal stimulation was seen when a 1:1 ratio or 1:2 ratio of responding cell:stimulating cells of each cell line was utilized. The stimulating capacity of ARH-77 or RPMI-8226 cells was significantly diminished when a 1:4 ratio of responding cells:stimulating cells was utilized. Fresh bone marrow cells containing more than 80% plasma cells from a patient with multiple myeloma, on the other hand, failed to exert the stimulating capacity on two occasions. The striking difference between cultured myeloma cells and fresh plasma cells is that the Ia-like antigen is present on cultured myeloma cells, and this antigen is absent on fresh plasma cells. The relationship between the Ia-like antigen and the stimulating capacity in 'one-way' mixed lymphocyte reaction is discussed.

Antigens, Neoplasm↗
PubMed1979

Human thymus cells: a study of rosette-forming capacity with unsensitized and sensitized erythrocytes of various species.

Human thymus cells from 117 donors aged 2 months to 15 years, were studied for rosette-forming capacity with unsensitized and sensitized erythrocytes of various species. Viability of the thymus cells at the completion of isolation ranged from 95 to 99%. Over 90% of the total population of thymus cells were identified as T lymphocytes by either standard Es-rosette assay utilizing a 4 degree incubation with preceding centrifugation or T--LCL assay, on the average. Gravity Es-rosette assay high affinity Es-rosette assay, stable Es-rosette assay or active Es-rosette assay for identification of subsets of T lymphocytes indicate that most of the human thymus cells were capable of forming rosettes with unsensitized sheep erythrocytes at higher degrees of temperature with or without preceding centrifugation. Approximately half of the human thymus cells were also capable of forming rosettes with unsensitized allogeneic erythrocytes. Less than 3% of the thymus cells expressed receptors for the Fc portion of IgG (T gamma suppressor cells) whereas less than 1% of thymus cells expressed receptors for the Fc portion of IgM (T mu helper cells), indicating that most of the thymus cells are non-T mu/non T gamma cells. Only 1% or less of the thymus cells were identified as B cells by the SIg assay, the Em-rosette assay or the Ia-like antigen assay. There was no significant difference of any rosette assay between males and females or among various age groups.

Adolescent↗
PubMed1979

Isolation of T-cells, B-cells and macrophages by a two-stage adherence procedure.

This communication describes a method to obtain enriched populations of T-cells, B-cells and macrophages. Spleen cells were initially fractionated on nylon wool columns. The nylon wool adherent fraction was removed by mechanical agitation and further separated on the basis of adherence to a coated-plastic surface in the presence of autologous serum. The tissue flask adherent population was removed with the aid of a rubber policeman. The nylon wool non-adherent and the tissue flask non-adherent and adherent fractions were characterized for the presence of cell surface markers, size, and functional activity and were identified as T-cells, B-cells and macrophages, respectively. The two-stage adherence procedure is simple to perform and does not require sophisticated equipment or expensive reagents.

Animals↗